Key Lipoprotein Receptor Targeted Echinacoside-Liposomes Effective Against Parkinson’s Disease in Mice Model

• DOI: 10.2147/ijn.s468942
• Publication Date: 2024-08-19T08:10:35Z
• Authors: Zemin Ou; Yun You; Hong Yi; Xiaoqian Liu; Yan Tong; Dewen Liu; Jinyu Wang
• Keywords: Male; Dopaminergic Neurons; Brain; Parkinson Disease; Cell Line; Polyethylene Glycols; Mice, Inbred C57BL; Disease Models, Animal; Mice; Neuroprotective Agents; Blood-Brain Barrier; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Liposomes; Animals; Glycosides; Original Research

Introduction: Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in substantia nigra.The precise molecular mechanisms underlying neuronal loss PD remain unknown, and there are currently no effective treatments for PD-associated neurodegeneration.Echinacoside (ECH) known its neuroprotective effects, which include scavenging cellular reactive oxygen species promoting mitochondrial fusion.However, blood-brain barrier (BBB) limits bioavailability ECH brain, posing significant challenge to use treatment.Methods: We synthesized PEGylated liposomes (ECH@Lip) peptide angiopep-2 (ANG) modified (ECH@ANG-Lip).The density ANG ANG-Lip was optimized using bEnd.3cells.The brain-targeting ability assessed vitro transwell BBB model vivo an imaging system LC-MS.We evaluated enhanced properties this formulation 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model. Results:The ECH@ANG-Lip demonstrated significantly higher whole-brain uptake compared ECH@Lip free ECH.Furthermore, more mitigating MPTP-induced behavioral impairment, oxidative stress, dopamine depletion, neuron death than both ECH. Conclusion:The used our study efficacy model.Thus, shows considerable potential improving providing effects brain.